Compare Dynatrace Inc. Common Stock (DT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dynatrace Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? Dynatrace Inc. Common Stock trades at $63.33 (market cap $18.63B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Dynatrace Inc. Common Stock is far larger — about 5× Tango Therapeutics Inc.'s market cap, and Dynatrace Inc. Common Stock is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dynatrace Inc. Common Stock for 3 Days and Tango Therapeutics Inc. for 0 Days on average.
| DT | TNGX | |
|---|---|---|
Market Cap | $18.63B | $3.75B |
Volume | 8,438,411 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $65.25 | $32.90 |
52-Week Low | $32.36 | $7.50 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $17.68B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dynatrace (DT) trades at $64.46, down 1.21% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported robust revenue growth to $1.70B in 2025 and has consistently beaten earnings estimates, though its valuation ratios like a P/E of 128.94 are elevated. Recent developments include achieving FedRAMP certification and completing the acquisition of Arize, enhancing its AI observability platform.
The outlook is positive given strong analyst support (85.71% buy ratings) and a consensus price target of $62.44, though risks include high valuation sensitivity and projected net income decline in 2026. Earnings growth and federal market expansion are key catalysts, but investors should monitor execution against lofty expectations.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dynatrace Inc. Common Stock
Dynatrace provides an observability, security, and automation platform for cloud and IT environments. Its platform integrates data such as logs, metrics, and traces to help organizations monitor digital systems.
Read more on DT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
